Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.
Data reveal prevalence of advanced prostate cancer states
May 18th 2020Findings from a systematic literature review further our understanding of the prevalence of distinct clinical states of advanced prostate cancer, their association with homologous recombination repair (HRR) gene alterations, and the use of testing methods to identify HRR gene alterations, researchers say.
MOSES-enabled pulsed laser allows same-day discharge without catheter
May 18th 2020The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.
Marketing used by men’s health clinics is cause for concern
May 14th 2020Findings from a study characterizing the providers and services offered by stand-alone commercialized men’s health clinics should be eye-opening and alarming for urologists, said Jagan K. Kansal, MD, MBA, at the American Urological Association 2020 Virtual Experience.
Blue light cystoscopy enables earlier detection of invasive bladder tumors
May 14th 2020Analyses of data from a multi-institutional registry show that blue light cystoscopy using hexaminolevulinate HCl (Cysview) detects invasive bladder tumors that are missed by white light cystoscopy in an appreciable number of patients.
Mixed incontinence patients show low risk for needing SUI surgery
May 13th 2020Women with mixed urinary incontinence seeking surgical intervention for refractory urinary urge incontinence have the same low risk of subsequently needing surgery for stress urinary incontinence whether they are treated with intradetrusor onabotulinumtoxinA (BTX [Botox]) injections or sacral neuromodulation.
Study adds to evidence linking anticholinergics, dementia
May 11th 2020Patients using anticholinergic medications for the management of overactive bladder (OAB) are at increased risk of new-onset dementia compared with individuals treated with the beta-3 agonist mirabegron (Myrbetriq), according to findings of a new population-based, retrospective study published online March 13, 2020, in BJU International.
NDA submitted for first oral GnRH receptor antagonist for prostate Ca
May 4th 2020After meeting the primary endpoint in a phase 3 study, Myovant Sciences submitted a New Drug Application to the FDA seeking approval of relugolix, an oral nonpeptide gonadotropin-releasing hormone receptor antagonist, as a once-daily treatment for men with advanced prostate cancer.
PARP inhibitor extends PFS, OS in men with progressive mCRPC
May 4th 2020“The outcomes and experience in the PROfound trial… represent major progress in the treatment of advanced prostate cancer that historically has not been considered amenable to genomic mutation-targeted therapy,” says Maha Hussain, MD.
Study evaluates targeted FGFR3 therapy for UTUC vs. UTB
April 22nd 2020New results from a study investigating infigratinib in patients having metastatic urothelial carcinoma with activating FGFR3 mutations and/or fusions indicate that the investigational selective fibroblast growth factor receptor 1 to 3 (FGFR1-3) tyrosine kinase inhibitor may have greater activity for treating upper tract urothelial carcinoma than for urothelial carcinoma of the bladder.
Multifaceted approach addresses pandemic’s threat to prostate cancer care
April 21st 2020Christina Yi, chief operations officer at Dendreon, discussed the efforts being made by the biotech company and its employees to meet the needs of patients with advanced prostate cancer who have chosen treatment with sipuleucel-T (Provenge).
Hydrogel spacer lowers rectal bleeding vs. balloon immobilization treatment
April 13th 2020Results from 2 years of follow-up in men undergoing proton beam therapy for localized prostate cancer suggest that treatment with the rectal hydrogel spacer (SpaceOAR) provides better rectal sparing than rectal balloon immobilization.
SABR prolongs survival in men with oligometastatic PCa
April 6th 2020Stereotactic body radiation reduced the likelihood for future PSA rises and significantly prolonged survival in men with oligometastatic prostate cancer (≤3 metastases), according to recently published findings from ORIOLE, a phase II, multicenter, randomized, observation-controlled trial.
Pharmacotherapy reduces recurrence risk for aggressive stone disease
February 28th 2020Pharmacotherapy for reducing risk of stone recurrence is best reserved for patients with more aggressive disease who are at higher risk for another stone-related event, said Brett A. Johnson, MD, at the 2019 World Congress of Endourology and SWL in Abu Dhabi.
Panel issues urology-specific opioid Rx recommendations
February 26th 2020Recommendations on opioid prescribing after endourologic and minimally invasive urologic surgery from an expert panel should help urologists align individual prescribing habits with current evidence, reduce opioid overprescribing, and provide a framework for refining patient-centered guidelines for opioid stewardship in urology, said Kevin Koo, MD, MPH, MPhil.
Intervention reduces post-RP opioid prescriptions
February 26th 2020A simple intervention aiming to curb the contribution of postoperative pain medication prescribing to the opioid crisis was shown to reduce post-discharge opioid prescribing and use and increase opioid disposal without seeming to jeopardize pain control for patients who had undergone radical prostatectomy.
Long-term QoL data support adding chemo to RT for localized MIBC
February 17th 2020“Our study showed that at least with the regimen used in our trial, patients can have chemotherapy in addition to radiotherapy without any fear that it will impair their quality of life,” says researcher Robert A. Huddart, MD, PhD.
Investigational urothelial Ca Tx undergoing priority review by FDA
February 17th 2020“In the OLYMPUS trial, more than half of patients receiving the gel had complete regression of their cancers, and most of the responses were durable. Based on these results, if UGN-101 is approved, it can be strongly considered as a kidney-sparing option for a challenging cancer," says John L. Gore, MD, MS.
Bladder cancer biomarker test accurately adjudicates atypical cytology
February 5th 2020“The results of our retrospective study support taking advantage of the Cxbladder test to identify patients who should be further evaluated for cancer and to spare those who likely do not have cancer from an unnecessary workup," says Badrinath Konety, MD, MBA.